A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-24. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
In 2009, the Justice Department reported that Mexican drug cartels distribute drugs in nearly 200 cities across the United States, including Los Angeles, Chicago, and Atlanta. Gang-related activity and violence has increased along the U.S. Southwest border region, as U.S.-based gangs act as enforcers for Mexican drug cartels. In October 2025, Mexican cartels are issuing bounties up to $50,000 for a hit on ICE and CBP agents according to the Department of Homeland Security.
== Total synthesis == The total synthesis of moroidin has not yet been described. Partial syntheses including the Leu-Trp and Trp-His linkages have been achieved. In their total synthesis of celogentin C, Castle and coworkers first obtained the Leu-Trp cross-link. The formation of this bond involved an intermolecular Knoevenagel condensation followed by radical conjugate addition and nitro reduction. This gave a product mixture of diastereomers, with the major product having the desired configuration. A second approach by Jia and coworkers employed an asymmetric Michael addition and bromination, a stereoselective reaction that gave a compound with the correct configuration and Leu-Trp linkage. Chen and coworkers demonstrated another stereoselective approach, which coupled iodotryptophan to 8-aminoquinoline by palladium catalysis to give a single diastereomer with the desired Leu-Trp linkage and configuration.
=== Effects === Behavioral effects can vary by dosage. Low doses produce numbness in the extremities and intoxication, characterized by staggering, unsteady gait, slurred speech, bloodshot eyes, and loss of balance. Moderate doses (5–10 mg intranasal, or 0.01–0.02 mg/kg intramuscular or intravenous) will produce analgesia and anesthesia. High doses may lead to convulsions. The drug is often illegally produced under poorly controlled conditions; this means that users may be unaware of the actual dose they are taking. Psychological effects include severe changes in body image, loss of ego boundaries, paranoia, and depersonalization. Psychosis, agitation and dysphoria, hallucinations, blurred vision, euphoria, and suicidal impulses are also reported, as well as occasional aggressive behavior. PCP may induce feelings of strength, power, and invulnerability as well as a numbing effect on the mind. Studies by the Drug Abuse Warning Network in the 1970s show that media reports of PCP-induced violence are greatly exaggerated and that incidents of violence are unusual and often limited to individuals with reputations for aggression regardless of drug use. Although uncommon, events of PCP-intoxicated individuals acting in an unpredictable fashion, possibly driven by their delusions or hallucinations, have been publicized. Other commonly cited types of incidents include inflicting property damage and self-mutilation of various types, such as pulling out one's teeth.
Sources: en.wikipedia.org
=== Fortification === Some countries require or recommend fortification of grain foods. As of 2024, 57 countries, mostly in North and South America and southeast Africa, require food fortification of wheat flour or maize (corn) flour with riboflavin or riboflavin-5'-phosphate sodium. The amounts stipulated range from 1.3 to 5.75 mg/kg. An additional 16 countries have a voluntary fortification program. For example, the Indian government recommends 4.0 mg/kg for "maida" (white) and "atta" (whole wheat) flour.
Chemical engineering – Engineering discipline focused on the design and operation of chemical plants Chemical reactor – Enclosed volume where interconversion of compounds takes place Medical science liaison – Connecting biotechnology and health care Pharmaceutical formulation – Process for producing a final medicinal product Pharmaceutical packaging – Packaging for pharmaceutical preparationsPages displaying short descriptions of redirect targets Site Master File – Synthesis of pharmaceutical drugsPages displaying short descriptions of redirect targets 3D drug printing – 3D printing of customized medicationPages displaying short descriptions of redirect targets
=== RNA editing in plant mitochondria and plastids === It has been shown in previous studies that the only types of RNA editing seen in the plants' mitochondria and plastids are conversion of C-to-U and U-to-C (very rare). RNA-editing sites are found mainly in the coding regions of mRNA, introns, and other non-translated regions. In fact, RNA editing can restore the functionality of tRNA molecules. The editing sites are found primarily upstream of mitochondrial or plastid RNAs. While the specific positions for C to U RNA editing events have been fairly well studied in both the mitochondrion and plastid, the identity and organization of all proteins comprising the editosome have yet to be established. Members of the expansive PPR protein family have been shown to function as trans-acting factors for RNA sequence recognition. Specific members of the MORF (Multiple Organellar RNA editing Factor) family are also required for proper editing at several sites. As some of these MORF proteins have been shown to interact with members of the PPR family, it is possible MORF proteins are components of the editosome complex. An enzyme responsible for the trans- or deamination of the RNA transcript remains elusive, though it has been proposed that the PPR proteins may serve this function as well. RNA editing is essential for the normal functioning of the plant's translation and respiration activity. Editing can restore the essential base-pairing sequences of tRNAs, restoring functionality.
The band was advised Kinney's health issue needed "immediate attention" and he was unfit to perform the scheduled dates, though they stated "his long-term prognosis is positive." In a September 2025 interview with Cleveland.com, Cantrell stated that Alice in Chains "had a tour planned for, like, right now that kind of fell through", adding, "So we had some bad luck; we planned on doing much more this year, but it just didn't work out." He also commented on the possibility of the band touring or recording a new album in 2026: "We'll take a look at it again probably early next year and figure out what we're gonna do, whether go in and make another record or do some shows—or both."
Sources: en.wikipedia.org
By August 2000, the United States' National Intelligence Estimate argued that the movement had failed due to democratic backsliding, corruption, and disease outbreaks. The weekend of September 28, 1998, some 470 participants attended the African Renaissance Conference in Johannesburg. The next year, a book titled African Renaissance was released, with thirty essays arranged under topics corresponding to the conference's breakout sessions: "culture and education, economic transformation, science and technology, transport and energy, moral renewal and African values, and media and telecommunications." Mbeki, the keynote speaker at the opening plenary session of the conference, wrote the book's prologue. Other figures associated with the African Renaissance and the new generation of African leaders are President Yoweri Museveni of Uganda and President Paul Kagame of Rwanda.
== See also == 2026 state visit by Donald Trump to China 2026 G20 Miami summit China–United States relations List of international trips made by Xi Jinping APEC China 2026 List of international presidential trips made by Donald Trump
== Advantages == APPI is most used for LC/MS although it has recently found widespread use in ambient applications such as detection of explosives and narcotics compounds for security applications using ion mobility spectrometry. Compared to the more commonly used predecessor ionization sources ESI and APCI, APPI ionizes a broader range of compounds with the benefit increasing toward the non-polar end of the scale. It also has relatively low susceptibility to ion suppression and matrix effects, which makes APPI very effective in detecting compounds quantitatively in complex matrices. APPI has other advantages including a broader linear range and dynamic range than ESI as seen by the example in the left figure. It is also generally more selective than APCI with reduced background ion signals as shown in the right figure. This latter example also highlights the benefit of APPI vs. ESI in that the HPLC conditions were for non-polar normal-phase in this case using n-hexane solvent. ESI requires polar solvents and further hexane could pose an ignition hazard for ESI and APCI that use high voltages. APPI works well under normal-phase conditions since many of the solvents are photoionizable and serve as dopant ions, which allows specialized applications such as separation of enantiomers (right figure).
== Research == Moxidectin is being evaluated as a treatment for scabies. It is established in veterinary medicine to treat a range of parasites, including sarcoptic mange. Its advantage over ivermectin is its longer half-life in humans, thus the potential duration of action.
The density of francium is expected to be around 2.48 g/cm3 (Mendeleev's method extrapolates 2.4 g/cm3). Another calculation gives a much higher value of 3.57 g/cm3. Francium is predicted to have a bulk modulus of 2.1–2.6 GPa. Linus Pauling estimated the electronegativity of francium at 0.7 on the Pauling scale, the same as caesium; the value for caesium has since been refined to 0.79, but there are no experimental data to allow a refinement of the value for francium. Francium has a slightly higher ionization energy than caesium, 392.811(4) kJ/mol as opposed to 375.7041(2) kJ/mol for caesium, as would be expected from relativistic effects, and this would imply that caesium is the less electronegative of the two. Francium should also have a higher electron affinity than caesium and the Fr− ion should be more polarizable than the Cs− ion.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.